14 September 2021
Ebola vaccine regimen generates strong immune response in children and adults in a clinical trial in Sierra Leone
Johnson & Johnson’s two-dose Ebola vaccine regimen is safe, well tolerated and produces a strong immune response in people over the age of one, according to two new papers published in The Lancet Infectious Diseases. The EBOVAC-Salone study provides important further evidence for the potential of the regimen using the Ad26.ZEBOV and MVA-BN-Filo vaccines to be used as a protective measure against Ebola virus disease for both children and adults.
Conducted in Sierra Leone, the study is the first to assess the safety and tolerability of this vaccine regimen in a region affected by the 2014-2016 West African Ebola outbreak, which was the worst on record. It is also the first study reporting the evaluation of this vaccine regimen in children.
4 June 2021
Statement on the SAGE Recommendation Regarding the Johnson & Johnson Ebola Vaccine Regimen
Johnson & Johnson welcomes the recommendation by the Strategic Advisory Group of Experts (SAGE) on Immunization for the World Health Organization (WHO) in support of the use of Johnson & Johnson’s two-dose Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), both during outbreaks for individuals at some risk of Ebola exposure and preventively, before outbreaks, for national and international first responders.
13 May 2021
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
Johnson & Johnson announces that the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company’s Ebola vaccine regimen, developed by Janssen Pharmaceutical Companies in collaboration with Bavarian Nordic A/S, as part of a WHO early access clinical program aimed at preventing further spread of Ebola in West Africa. The Ebola vaccine regimen has also received Prequalification from the WHO, which will help accelerate its registration in countries where Ebola is a persistent public health threat and facilitate broader access to people at risk of exposure to this virus.
1 July 2020
Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine
Johnson & Johnson announces that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies’ Ebola vaccine regimen for the prevention of Ebola Virus Disease. Two Marketing Authorisation Applications (MAAs) were submitted to the European Medicines Agency (EMA) for the vaccines composing the two-dose regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo).
29 May 2020
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen
Johnson & Johnson announces that its Janssen Pharmaceutical Companies received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its investigational Ebola vaccine regimen for the prevention of the Ebola Virus Disease caused by the Zaire ebolavirus species.
